Work

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial

Year: 2017

Type: article

Source: Respiratory Medicine

DOI: 10.1016/j.rmed.2017.07.060

Authors: Courtney Crim, Peter M.A. Calverley, Julie A. Anderson, Andrew P. Holmes, Sally Kilbride, Fernando J. Martinez, Robert D. Brook, David E. Newby, Julie C. Yates, Bartolomé R. Celli, Jørgen Vestbo

Institutions: GlaxoSmithKline (United States), Aintree University Hospital, GlaxoSmithKline (United Kingdom), NewYork–Presbyterian Hospital, Michigan Medicine, University of Edinburgh, Brigham and Women's Hospital, Harvard University, University of Manchester

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: North Carolina GlaxoSmithKline Foundation

Awards: G1565981679, G4157537563

OpenAlex ID: W2740353415

FWCI: 4.75

Cites: 24

Cited by: 37

Related to: 10